Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EGL-001 |
Synonyms | |
Therapy Description |
EGL-001 is an immunocytokine comprising an anti-CTLA-4 IgG1 linked to an IL-2 mutein that binds to IL2RA (CD25) expressed on T-regulatory cells, potentially resulting in decreased IL2RA-mediated signaling, reduced immunosuppression, and enhanced antitumor activity (Cancer Res (2024) 84 (6_Supplement): 4079). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EGL-001 | EGL 001|EGL001 | EGL-001 is an immunocytokine comprising an anti-CTLA-4 IgG1 linked to an IL-2 mutein that binds to IL2RA (CD25) expressed on T-regulatory cells, potentially resulting in decreased IL2RA-mediated signaling, reduced immunosuppression, and enhanced antitumor activity (Cancer Res (2024) 84 (6_Supplement): 4079). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06622486 | Phase Ib/II | EGL-001 EGL-001 + unspecified PD-L1 antibody | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | Recruiting | FRA | ESP | 0 |